Skip to main content

Cognition Therapeutics Inc

CGTX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001455365

No open-market purchases or sales by Cognition Therapeutics Inc insiders were filed in the last 90 days; 66 institutions reported holding it in 13F filings for Q2 2026, worth $26.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Cognition Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Cognition Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Cognition Therapeutics Inc
NameTitleLast reported holdingLast filingFilings, past year
BIOS Memory SPV I, LPDirector, 10% Owner81,229Jun 22, 20261
BIOS Fund I, LPDirector, 10% Owner81,229Jun 22, 20261
BIOS Fund I QP, LPDirector, 10% Owner81,229Jun 22, 20261
BIOS Fund II, LPDirector, 10% Owner81,229Jun 22, 20261
BIOS Fund II QP, LPDirector, 10% Owner81,229Jun 22, 20261
Fletcher Aaron G.L.Director, 10% Owner81,229Jun 22, 20261
Bios Equity Partners II, LPDirector, 10% Owner81,229Jun 22, 20261
Bios Equity Partners, LPDirector, 10% Owner81,229Jun 22, 20261
BIOS Advisors GP, LLCDirector, 10% Owner81,229Jun 22, 20261
BIOS Capital Management, LPDirector, 10% Owner81,229Jun 22, 20261
Richstone Ellen BDirector83,500Jun 22, 20261
Monia Brett PDirector73,500Jun 22, 20261
Khattar Jack A.Director73,500Jun 22, 20261
Wallace PeggyDirector111,461Jun 22, 20261
Doyle John BrendanChief Financial Officer618,942May 4, 20265
Ricciardi LisaCEO & President1,715,851Apr 20, 20264
Caggiano AnthonyChief Medical Officer874,906Apr 20, 20264
BIOS Memory SPV II, LPDirector, 10% Owner48,500IndirectJun 20, 20250
BIOS Fund II NT, LPDirector, 10% Owner48,500IndirectJun 20, 20250
BIOS Fund III NT, LPDirector, 10% Owner48,500IndirectJun 20, 20250
BIOS Fund III QP, LPDirector, 10% Owner48,500IndirectJun 20, 20250
BIOS Fund III, LPDirector, 10% Owner48,500IndirectJun 20, 20250
Cavu Management, LPDirector, 10% Owner48,500IndirectJun 20, 20250
Cavu Advisors, LLCDirector, 10% Owner48,500IndirectJun 20, 20250
BP Directors, LPDirector, 10% Owner48,500IndirectJun 20, 20250
Kreis Leslie W.Director, 10% Owner48,500IndirectJun 20, 20250
BIOS Equity Partners III, LPDirector, 10% Owner48,500IndirectJun 20, 20250
Golden Seeds Cognition Therapeutics LLC10% Owner0Sep 29, 20220
O'Brien James MichaelChief Financial Officer5,000Mar 25, 20220
Ogden CAP Associates, LLC10% Owner2,210,377Oct 15, 20210
Breedlove Mark H.Director404,439IndirectOct 15, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 20, 2026 (view filing)Apr 164 daysDoyle John BrendanChief Financial OfficerPPurchase+10.0K$1.13+$11.3K+1.6%627.5K after
Apr 20, 2026 (view filing)Apr 164 daysRicciardi LisaCEO & PresidentPPurchase+9.18K$1.10+$10.1K+0.5%1.72M after
Apr 20, 2026 (view filing)Apr 164 daysCaggiano AnthonyChief Medical OfficerPPurchase+10.0K$1.11+$11.1K+1.2%874.9K after
Feb 4, 2025 (view filing)Jan 314 daysRicciardi LisaCEO & PresidentPPurchase+38.9K$0.77+$29.9KNew position38.9K after
Mar 14, 2024 (view filing)Mar 14Same dayRicciardi LisaCEO & PresidentPPurchase+5.70K$1.75+$9.97K+2.0%291.3K after
Nov 29, 2022 (view filing)7:02 AM ETNov 281 dayBIOS Memory SPV I, LP and 9 othersDirector, 10% OwnerPPurchase+16.1K$2.65+$42.6K+5.5%309.7K after3 lotsDuplicate filing
Nov 29, 2022 (view filing)7:00 AM ETNov 281 dayBIOS Memory SPV II, LP and 8 othersDirector, 10% OwnerPPurchase+16.1K$2.65+$42.6K+5.5%309.7K after3 lots
Nov 29, 2022 (view filing)Nov 29Same dayRichstone Ellen BDirectorPPurchase+10.0K$2.66+$26.6KNew position10.0K after
Nov 17, 2022 (view filing)7:00 AM ETNov 161 dayFletcher Aaron G.L. and 9 othersDirectorPPurchase+71.0K$1.40+$99.4K+30.0%307.9K after3 lotsDuplicate filing
Nov 17, 2022 (view filing)7:00 AM ETNov 161 dayKreis Leslie W. and 8 othersDirectorPPurchase+71.0K$1.40+$99.4K+30.0%307.9K after3 lots
Nov 16, 2022 (view filing)7:00 AM ETNov 151 dayFletcher Aaron G.L. and 9 othersDirectorPPurchase+1.50M$1.20+$1.80MNew position299.6K after3 lotsDuplicate filing
Nov 16, 2022 (view filing)6:59 AM ETNov 151 dayKreis Leslie W. and 8 othersDirectorPPurchase+1.50M$1.20+$1.80MNew position299.6K after3 lots
Nov 16, 2022 (view filing)Nov 151 dayRicciardi LisaCEO & PresidentPPurchase+12.0K$1.30+$15.6K+96.0%24.5K after
Nov 16, 2022 (view filing)Nov 151 dayWallace PeggyDirectorPPurchase+12.5K$1.20+$15.0K+49.1%38.0K after
Oct 25, 2021 (view filing)Oct 1312 daysLateWallace PeggyDirectorPPurchase+3.00K$12.00+$36.0KNew position3.00K after
Oct 15, 2021 (view filing)9:54 PM ETOct 132 daysBIOS Memory SPV I, LP10% OwnerPPurchase+190.0K$12.00+$2.28M+26.8%899.9K after3 lotsDuplicate filing
Oct 15, 2021 (view filing)9:54 PM ETOct 132 daysBIOS Memory SPV I, LP10% OwnerSSale−90.28$12.00−$1.08K0.0%385.2K afterDuplicate filing
Oct 15, 2021 (view filing)9:51 PM ETOct 132 daysFletcher Aaron G.L.DirectorPPurchase+190.0K$12.00+$2.28M+26.8%899.9K after3 lots
Oct 15, 2021 (view filing)9:51 PM ETOct 132 daysFletcher Aaron G.L.DirectorSSale−90.28$12.00−$1.08K0.0%385.2K after
Oct 15, 2021 (view filing)9:51 PM ETOct 132 daysGolden Seeds Cognition Therapeutics LLC10% OwnerSSale−33.09$12.00−$397.080.0%2.18M after
Oct 15, 2021 (view filing)9:51 PM ETOct 132 daysOgden CAP Associates, LLC10% OwnerSSale−74.05$12.00−$888.60.0%2.21M after
Oct 15, 2021 (view filing)9:02 PM ETOct 132 daysBreedlove Mark H.DirectorSSale−11.74$12.00−$140.880.0%404.4K after
Oct 14, 2021 (view filing)Oct 131 dayRicciardi LisaCEO & PresidentPPurchase+12.5K$12.00+$150.0KNew position12.5K after
Oct 14, 2021 (view filing)Oct 131 dayO'Brien James MichaelChief Financial OfficerPPurchase+5.00K$12.00+$60.0KNew position5.00K after